Previously, we reported a second-generation inhibitor of the hepatitis C virus NS3/4A protease: the discovery of BMS-986144 with pan-genotypic antiviral activity. As part of our continuous effort in search of a structurally differentiated backup to BMS-986144, we conducted computational molecular modeling studies that led to a specific focus around the P2* region. In this presentation, we will describe the discovery of BMS-986160, a potent HCV NS3 protease inhibitor that demonstrates superior pan-genotypic antiviral activity and excellent coverage of the highly resistant variants<i> in vitro</i>. The structure-activity relationship that led to the discovery of BMS-986160 will be described in detail along with preclinical characteristics.<br/>

Discovery of BMS-986160 as a second-generation inhibitor of the hepatitis C virus NS3/4A with pan-genotypic antiviral activity

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.